Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rallybio Corp.

0.4500
-0.1070-19.21%
Post-market: 0.48000.0300+6.67%19:27 EDT
Volume:183.95K
Turnover:88.32K
Market Cap:18.73M
PE:-0.34
High:0.6325
Open:0.5723
Low:0.4301
Close:0.5570
Loading ...

Rallybio Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
17 Mar

Rallybio’s Promising Financial Stability and Strategic Clinical Advancements Drive Buy Rating

TIPRANKS
·
14 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
14 Mar

Rallybio Corporation Reports 2024 Financial Results and Progress

TIPRANKS
·
14 Mar

Rallybio Corp -Entered Amendment No. 1 to Sales Agreement Dated August 8, 2022

THOMSON REUTERS
·
14 Mar

Rallybio Corp - Reduces Stock Sale Amount to $9.55 Million

THOMSON REUTERS
·
14 Mar

Promising Developments and Financial Stability Support Buy Rating for Rallybio

TIPRANKS
·
14 Mar

Rallybio Q4 EPS $(0.25) Beats $(0.29) Estimate, Sales $38.00K Miss $75.00K Estimate

Benzinga
·
13 Mar

BRIEF-Rallybio Q4 Net Income USD -11.044 Million

Reuters
·
13 Mar

Rallybio Q4 Basic EPS USD -0.25

THOMSON REUTERS
·
13 Mar

Rallybio Q4 Operating Expenses USD 11.646 Million

THOMSON REUTERS
·
13 Mar

Press Release: Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Dow Jones
·
13 Mar

Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Simply Wall St.
·
04 Mar

Rallybio Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Feb

BRIEF-Rallybio Announces Initiation Of Dosing In RLYB212 Phase 2 Clinical Trial

Reuters
·
11 Feb

Rallybio announces initiation of dosing in RLYB212 Phase 2 trial

TIPRANKS
·
11 Feb

Rallybio Corp - Pk and Safety Data Expected in 2Q and 3Q 2025

THOMSON REUTERS
·
11 Feb

Rallybio Announces Initiation of Dosing in Rlyb212 Phase 2 Clinical Trial

THOMSON REUTERS
·
11 Feb

Rallybio Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Jan

Rallybio’s Promising Pipeline and Clinical Milestones Earns Buy Rating from Analyst Jonathan Wolleben

TIPRANKS
·
11 Jan